Please use this identifier to cite or link to this item: http://hdl.handle.net/2445/172326
Title: Assessment of Platelet REACtivity After Transcatheter Aortic Valve Replacement: The REAC-TAVI Trial
Author: Jimenez Diaz, Victor Alfonso
Tello-Montoliu, Antonio
Moreno Aguado, Víctor
Cruz Gonzalez, Ignacio
Baz Alonso, Jose Antonio
Romaguera, Rafael
Molina Navarro, Eduardo
Juan Salvadores, Pablo
Paredes Galan, Emilio
De Miguel Castro, Antonio
Bastos Fernandez, Guillermo
Ortiz Saez, Alberto
Fernandez Barbeira, Saleta
Raposeiras Roubin, Sergio
Ocampo Miguez, Juan
Serra Peñaranda, Antonio
Valdes Chavarri, Mariano
Cequier Fillat, Àngel R.
Calvo Iglesias, Francisco
Iñiguez Romo, Andres
Keywords: Síndrome de Williams
Agregació plaquetària
Williams syndrome
Blood platelet aggregation
Issue Date: 14-Jan-2019
Publisher: Elsevier
Abstract: OBJECTIVES: The REAC-TAVI (Assessment of platelet REACtivity after Transcatheter Aortic Valve Implantation) trial enrolled patients with aortic stenosis (AS) undergoing transcatheter aortic valve replacement (TAVR) pre-treated with aspirin + clopidogrel, aimed to compare the efficacy of clopidogrel and ticagrelor in suppressing high platelet reactivity (HPR) after TAVI. BACKGROUND: Current recommendations support short-term use of aspirin + clopidogrel for patients with severe AS undergoing TAVR despite the lack of compelling evidence. METHODS: This was a prospective, randomized, multicenter investigation. Platelet reactivity was measured at 6 different time points with the VerifyNow assay (Accriva Diagnostics, San Diego, California). HPR was defined as (P2Y12 reaction units (PRU) ≥208. Patients with HPR before TAVR were randomized to either aspirin + ticagrelor or aspirin + clopidogrel for 3 months. Patients without HPR continued with aspirin + clopidogrel (registry cohort). The primary endpoint was non-HPR status (PRU <208) in ≥70% of patients treated with ticagrelor at 90 days post-TAVR. RESULTS: A total of 68 patients were included. Of these, 48 (71%) had HPR (PRU 273 ± 09) and were randomized to aspirin + ticagrelor (n = 24, PRU 277 ± 08) or continued with aspirin + clopidogrel (n = 24, PRU 269 ± 49). The remaining 20 patients (29%) without HPR (PRU 133 ± 12) were included in the registry. Overall, platelet reactivity across all the study time points after TAVR was lower in patients randomized to ticagrelor compared with those treated with clopidogrel, including those enrolled in the registry (p < 0.001). The primary endpoint was achieved in 100% of patients with ticagrelor compared with 21% with clopidogrel (p < 0.001). Interestingly, 33% of clopidogrel responder patients at baseline developed HPR status during the first month after TAVR. CONCLUSIONS: HPR to clopidogrel is present in a considerable number of patients with AS undergoing TAVR. Ticagrelor achieves a better and faster effect, providing sustained suppression of HPR to these patients. (Platelet Reactivity After TAVI: A Multicenter Pilot Study [REAC-TAVI]; NCT02224066).
Note: Reproducció del document publicat a: https://doi.org/10.1016/j.jcin.2018.10.005
It is part of: Jacc-Cardiovascular Interventions, 2019, vol. 12, num. 1, p. 22-32
URI: http://hdl.handle.net/2445/172326
Related resource: https://doi.org/10.1016/j.jcin.2018.10.005
ISSN: 1936-8798
Appears in Collections:Articles publicats en revistes (Ciències Clíniques)

Files in This Item:
File Description SizeFormat 
689854.pdf1.33 MBAdobe PDFView/Open


This item is licensed under a Creative Commons License Creative Commons